David Hyman Purchases 20,000 Shares of Medicenna Therapeutics Corp. (TSE:MDNA) Stock

Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer David Hyman purchased 20,000 shares of the company’s stock in a transaction on Thursday, January 9th. The stock was purchased at an average price of C$1.45 per share, with a total value of C$29,000.00.

Medicenna Therapeutics Stock Down 5.5 %

MDNA opened at C$1.37 on Friday. The stock has a market cap of C$104.71 million, a price-to-earnings ratio of -3.61 and a beta of 1.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.65 and a current ratio of 2.51. The firm’s fifty day moving average is C$1.78 and its 200 day moving average is C$2.00. Medicenna Therapeutics Corp. has a fifty-two week low of C$0.40 and a fifty-two week high of C$2.98.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.